Skip to content

Source filing unavailable

Q2 2012 · —
Revenue$124.23M+92.4% vs Q2 2011+21.2% vs Q1 2012
Net Income$27.15M−18.2% vs Q2 2011−1.9% vs Q1 2012
EPS Diluted$0.45−36.6% vs Q2 2011−6.2% vs Q1 2012
Gross Profit$110,714,000+84.2%
Operating Income$39,427,000+16.4%
Operating Cash Flowderived$76,969,000+105.6%
Free Cash Flowderived$74,760,000+100.2%
Margins · derived
Gross margin89.1%−4.0 pt vs Q2 2011
Operating margin31.7%−20.7 pt vs Q2 2011
Net margin21.9%−29.6 pt vs Q2 2011

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2012Q2 2011Q2 2010
Revenue$124.23M$64.57M$64.57M
Net Income$27.15M$33.20M$33.20M
EPS Diluted$0.45$0.71$0.71

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR